SLC5A2 and prostate carcinoma: Only one phase 1 trial was registered in ClinicalTrials.gov (NCT04887935), which aims to investigate the safety of dapagliflozin, one type of SGLT2 inhibitor, for men considered at high risk of prostate cancer.